Novartis

Novartis still hasn't solved its lingering CAR-T manufacturing issues
Novartis still hasn't solved its lingering CAR-T manufacturing issues
Biopharma Dive
ASH2019
Novartis
FDA
CAR-T
drug manufacturing
Kymriah
Flag link:
Novartis Kymriah demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting
Novartis Kymriah demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting
Pharmaceutical Business Review
Novartis
Kymriah
CAR-T
DLBCL
ALL
Flag link:
Drug Launch of the Year: Zolgensma
Drug Launch of the Year: Zolgensma
Biopharma Dive
drug launches
Novartis
Zolgensma
SMA
Flag link:
With EMA review in progress, Novartis unveils more positive data on asthma therapy
With EMA review in progress, Novartis unveils more positive data on asthma therapy
Endpoints
Novartis
EMA
asthma
QMF149
clinical trials
Flag link:
While Novartis combats generic onslaught in the courts, FDA approves first Gilenya copycats
While Novartis combats generic onslaught in the courts, FDA approves first Gilenya copycats
Endpoints
Novartis
FDA
Gilenya
MS
multiple sclerosis
Mylan
Dr Reddy's
Torrent Pharmaceuticals
Aurobindo
generics
Flag link:
Novartis pulls rival to Roche’s risdiplam in SMA, says market limited
Novartis pulls rival to Roche’s risdiplam in SMA, says market limited
Pharmaforum
Novartis
Roche
SMA
risdiplam
branaplam
Flag link:
Novartis says mid-stage pipeline is setting up strong growth spurt
Novartis says mid-stage pipeline is setting up strong growth spurt
Pharmaforum
Novartis
Pharma CEOs
Vas Narasimhan
R&D
clinical trials
Flag link:
Novartis taps Amazon know-how for ‘smart’ manufacturing, supply chain
Novartis taps Amazon know-how for ‘smart’ manufacturing, supply chain
Pharmaforum
Novartis
Amazon
drug manufacturing
distribution
Flag link:
Gene Therapy M&A Appetite Provides Lift After Audentes Deal
Gene Therapy M&A Appetite Provides Lift After Audentes Deal
Yahoo/Bloomberg
gene therapy
Astellas
Audentes Therapeutics
M&A
Novartis
Medicines Company
Flag link:
Why Novartis's $9.7 Billion Purchase of The Medicines Company Is Bad News for Amgen
Why Novartis's $9.7 Billion Purchase of The Medicines Company Is Bad News for Amgen
Motley Fool
Novartis
Medicines Company
M&A
inclisiran
Flag link:
Novartis opens new cell and gene therapies facility in Switzerland
Novartis opens new cell and gene therapies facility in Switzerland
Pharmaceutical Business Review
Novartis
cell therapy
gene therapy
Switzerland
Flag link:
Drugs firms make massive discounts to get reimbursement in China
Drugs firms make massive discounts to get reimbursement in China
Pharmaforum
Roche
Novartis
China
reimbursement
Flag link:
FDA Approves 5 New Costly Drugs Well Ahead of PDUFA Dates
FDA Approves 5 New Costly Drugs Well Ahead of PDUFA Dates
RAPS.org
FDA
Vertex Pharmaceuticals
Trikafta
Novartis
Adakveo
Alnylam
Givlaari
BeiGene
Brukinsa
Global Blood Therapeutics
Oxbryta
drug approvals
Flag link:
Pfizer, Novartis lead $2 billion spending spree on gene therapy production
Pfizer, Novartis lead $2 billion spending spree on gene therapy production
Reuters
gene therapy
drug manufacturing
Pfizer
Novartis
Bluebird Bio
PTC Therapeutics
Krystal Biotech
Flag link:
Why Novartis Is Buying The Medicines Company For $9.7 Billion
Why Novartis Is Buying The Medicines Company For $9.7 Billion
Forbes
Novartis
Medicines Company
M&A
inclisiran
Flag link:
Amarin for $20B? Novartis' MedCo deal drives fresh buyout rumors for Vascepa's maker
Amarin for $20B? Novartis' MedCo deal drives fresh buyout rumors for Vascepa's maker
Fierce Pharma
Amarin
M&A
Novartis
Medicines Company
Gilead Sciences
Flag link:
Ex-Purdue CEO stands to earn a huge windfall in Novartis' buyout of the Medicines Co
Ex-Purdue CEO stands to earn a huge windfall in Novartis' buyout of the Medicines Co
Endpoints
Mark Timney
Purdue Pharma
Novartis
Medicines Company
M&A
Flag link:
Novartis buys Medicines Co. in $9.7B bet on cholesterol drug
Novartis buys Medicines Co. in $9.7B bet on cholesterol drug
Biopharma Dive
Novartis
The Medicines Company
M&A
Flag link:
Global Blood Therapeutics Goes Head to Head With Novartis On Sickle Cell
Global Blood Therapeutics Goes Head to Head With Novartis On Sickle Cell
Motley Fool
Global Blood Therapeutics
voxelotor
Novartis
Adakveo
sickle cell disease
Flag link:
Which asthma biologic do docs prefer? It's not that simple: analyst
Which asthma biologic do docs prefer? It's not that simple: analyst
Fierce Pharma
asthma
Roche
Novartis
Xolair
Sanofi
Regeneron
Dupixent
physicians
Flag link:

Pages